Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age.

The retinal vein occlusion drugs in development market research report provides comprehensive information on the therapeutics under development for retinal vein occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for retinal vein occlusion and features dormant and discontinued projects.

What are the key targets in the retinal vein occlusion pipeline products market?

The key targets in the retinal vein occlusion pipeline products market are vascular endothelial growth factor, vascular endothelial growth factor A, glucocorticoid receptor, phospholipase A2, placenta growth factor, protein kinase C, vascular endothelial growth factor receptor 2, angiopoietin 1 receptor, angiopoietin 2, calpain 1 catalytic subunit, and others.

Retinal Vein Occlusion Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the retinal vein occlusion pipeline products market?

The key mechanisms of action in the retinal vein occlusion pipeline products market are vascular endothelial growth factor inhibitor, vascular endothelial growth factor A inhibitor, phospholipase A2 inhibitor, placenta growth factor inhibitor, protein kinase C inhibitor, glucocorticoid receptor agonist, vascular endothelial growth factor receptor 2 inhibitor, angiopoietin 1 receptor agonist, angiopoietin 2 inhibitor, calpain 1 catalytic subunit inhibitor, and others.

Retinal Vein Occlusion Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of action insights, download a free report sample

What are the key routes of administration in the retinal vein occlusion pipeline products market?

The key routes of administration in the retinal vein occlusion pipeline products market are intravitreal, intravenous, intraocular, ophthalmic, and topical.

Retinal Vein Occlusion Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the different molecule types in the retinal vein occlusion pipeline products market?

The different molecule types in the retinal vein occlusion pipeline products market are small molecule, monoclonal antibody, synthetic peptide, fusion protein, recombinant protein, gene therapy, aptamer, monoclonal antibody conjugated, and protein.

Retinal Vein Occlusion Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Which are the major companies in the retinal vein occlusion pipeline products market?

The major companies in the retinal vein occlusion pipeline products market are ANBITION Srl, Ocular Therapeutix Inc, Annexin Pharmaceuticals AB, Avirmax Inc, Kala Pharmaceuticals Inc, Ripple therapeutics Corp, 3SBio Inc, Allgenesis Biotherapeutics Inc, AsclepiX Therapeutics Inc, and Calpain Therapeutics Pty Ltd.

Retinal Vein Occlusion Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Scope

• The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion
• The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Retinal Vein Occlusion therapeutics and enlists all their major and minor projects
• The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews the latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus on Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from the pipeline